Heterogeneity of EGFR mutations in a patient treated with gefitinib as neo-adjuvant chemotherapy

These results suggest that there may be intratumoral heterogeneity of EGFR mutations, and the therapeutic effect of EGFR-TKIs could be limited only to mutant cells.